BMS-496

• Description :

  BMS-496 is adualDGKα/ζlipid kinase inhibitor, with theIC50of 0.09 (DGKα) and 0.006 μM (DGKζ) [1].

• UNSPSC :

  12352005

• Target :

  DGK

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/bms-496.html

• Purity :

  99.72

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  CN(C1=CC=C(Br)N=C1C(N2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)=C5[N+]([O-])=O)C5=O

• Molecular Formula :

  C26H22BrF2N5O3

• Molecular Weight :

  570.39

• References & Citations :

  [1]Wichroski M, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023;15 (719) :eadh1892.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2407854-31-1]